Pharmacokinetics hydroxyurea

Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 1998, 34 347-358. 

The foundation for further study of combination regimens with hydroxyurea and 5-FU is based on in vitro pharmacokinetics denoting modulation of 5-FU by depleting deoxyuridine monophosphate (dUMP), ametabolic product of 5-FU. In turn, this will allow increased binding of 5-FU to thymidylate synthase and augment the properties of 5-FU. 

Reardon DA et al (2009) Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115 2188-2198... 

In phase I, volunteer studies showed that the inhibition of c i ii o-stimulated LTB4 in blood correlated with plasma drug levels (139). Pharmacokinetic studies in phase I volunteers determined that the major route of metabolism of zileuton is glucuronidation of the N-hydroxyurea group followed by urinary excretion, and the oral half-life was estimated to be 3 h (140). With this relatively short half-life it was necessary to administer 600 mg four times a day (qid) to maintain ex i ii o-stimu-lated LTB4 inhibition in human blood at approximately 80% returning to control levels after removal of the drug. No untoward side effects were observed. 

Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol December 2013 88(12) 1068-73. 

---

See also in sourсe #XX -- [ ]

See also in sourсe #XX -- [ ]

---